Averin | Activity | F4Averin Activity
Every public signal F4 has attached to this firm, with sources and cross-entity links.
Podcast
David Berry podcast episode.
Entrepreneurial Impact Amplified
Essay
Eric Berry on who captures the value of AI-saved physician time.
AI Can Save Physicians Time. Where Does It Go?
Essay
David Berry on AI, automation, and data expanding the number of diseases that get treated.
The Case for Drug Abundance
Team Change
Former Pfizer CSO Mikael Dolsten joined as an advisor.
Mikael Dolsten, MD PhD joins Averin Advisory Board
Essay
Tomer Zitelny argues malpractice underwriting is the gating factor for clinical AI.
The Liability Gap: Why Underwriting Is the Real Unlock for Clinical AI
Podcast
David Berry on the Billion Dollar Moves podcast.
Picking Battles in the $5 Trillion Healthcare Market
News
Affiliated blank-check company Averin Capital Acquisition Corp. announced pricing of its $250M IPO.
Averin Capital Acquisition Corp. $250M IPO
Press
Eric Berry interview on Averin's origins and focus on clinical AI and care delivery.
5 Questions with Averin Capital's Eric Berry
Talk
Jeffrey Low appeared on a biopharma transactions panel.
Meeting the Moment in Biopharma Transactions (Ropes & Gray, Jefferies Global Healthcare Conference)
Team Change
The firm rebranded from Bedford Bridge to Averin.
Bedford Bridge is now Averin
Team Change
Jeffrey Low and Tristan Hunt were announced as Averin partners.
Jeffrey Low, MD and Tristan Hunt, MD join as Partners